MA45573A - Anticorps anti-cd154 et procédés d'utilisation correspondant - Google Patents

Anticorps anti-cd154 et procédés d'utilisation correspondant

Info

Publication number
MA45573A
MA45573A MA045573A MA45573A MA45573A MA 45573 A MA45573 A MA 45573A MA 045573 A MA045573 A MA 045573A MA 45573 A MA45573 A MA 45573A MA 45573 A MA45573 A MA 45573A
Authority
MA
Morocco
Prior art keywords
antibodies
corresponding methods
methods
Prior art date
Application number
MA045573A
Other languages
English (en)
Inventor
Johan Fransson
Jocelyn Leu
Galina Obmolova
Anish Suri
Fang Teng
Alexey Teplyakov
Hong Zhou
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA45573A publication Critical patent/MA45573A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
MA045573A 2015-08-05 2016-08-04 Anticorps anti-cd154 et procédés d'utilisation correspondant MA45573A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562201150P 2015-08-05 2015-08-05
US201662367660P 2016-07-28 2016-07-28

Publications (1)

Publication Number Publication Date
MA45573A true MA45573A (fr) 2019-05-15

Family

ID=57944010

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045573A MA45573A (fr) 2015-08-05 2016-08-04 Anticorps anti-cd154 et procédés d'utilisation correspondant

Country Status (26)

Country Link
US (2) US10669343B2 (fr)
EP (1) EP3331563B1 (fr)
JP (2) JP7049988B2 (fr)
KR (1) KR20180030917A (fr)
CN (2) CN107921128B (fr)
AU (1) AU2016301361B2 (fr)
BR (1) BR112018002319A2 (fr)
CA (1) CA2994825A1 (fr)
CL (1) CL2018000298A1 (fr)
CO (1) CO2018001256A2 (fr)
EA (1) EA201890434A1 (fr)
EC (1) ECSP18008922A (fr)
ES (1) ES2944982T3 (fr)
GT (1) GT201800034A (fr)
HK (1) HK1256804A1 (fr)
IL (2) IL293065A (fr)
MA (1) MA45573A (fr)
MX (1) MX2018001522A (fr)
MY (1) MY188405A (fr)
NI (1) NI201800017A (fr)
PE (1) PE20180802A1 (fr)
PH (1) PH12018500203B1 (fr)
SG (1) SG10201913275QA (fr)
SV (1) SV2018005624A (fr)
UA (1) UA123398C2 (fr)
WO (1) WO2017024146A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180030917A (ko) * 2015-08-05 2018-03-26 얀센 바이오테크 인코포레이티드 항-cd154 항체 및 그의 사용 방법
WO2017024264A2 (fr) 2015-08-05 2017-02-09 Eisai R&D Management Co., Ltd. Réactifs chiraux pour la préparation d'oligomères homogènes
AU2016360987A1 (en) 2015-11-27 2018-06-07 Ablynx Nv Polypeptides inhibiting CD40L
AU2019347730A1 (en) * 2018-09-24 2021-03-25 Janssen Biotech, Inc. Method of providing safe administration of an anti-CD154 antibody
JP7775080B2 (ja) * 2019-07-01 2025-11-25 トニックス ファーマ リミテッド 抗ｃｄ１５４抗体およびその使用
WO2021006604A1 (fr) * 2019-07-08 2021-01-14 주식회사 프로젠 Nouvelle protéine de fusion et son utilisation
US20230078330A1 (en) * 2020-01-27 2023-03-16 Vanderbilt University Human anti-dengue antibodies and methods of use therefor
WO2022025585A1 (fr) * 2020-07-28 2022-02-03 주식회사 엘지화학 Anticorps anti-lilrb1 et ses utilisations
CN117715941A (zh) * 2021-07-30 2024-03-15 首尔大学校产学协力团 抗cd154抗体及其用途
CN115586338A (zh) * 2022-09-20 2023-01-10 杭州赛基生物科技有限公司 用于检测可溶性细胞因子受体的试剂盒及其制备方法
CN121358768A (zh) * 2023-04-28 2026-01-16 信达生物制药(苏州)有限公司 抗cd40l抗体及其在人自身免疫疾病治疗的应用

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US541606A (en) 1895-06-25 Sealed package
US7709A (en) 1850-10-08 Chas S Gaylord Improved spring-grapple
US226A (en) 1837-06-03 Samuel goss
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
WO1988001649A1 (fr) 1986-09-02 1988-03-10 Genex Corporation Molecules de liaison de chaines de polypeptide simples
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
EP0940468A1 (fr) 1991-06-14 1999-09-08 Genentech, Inc. Domaine variable d'un anticorps humanisé
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
DE69233051T2 (de) 1991-10-25 2004-03-11 Immunex Corp., Seattle Antikörper gegen CD40-L
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
WO1994010308A1 (fr) 1992-10-23 1994-05-11 Immunex Corporation Procede de preparation de proteines oligomeres solubles
EP1005870B1 (fr) 1992-11-13 2009-01-21 Biogen Idec Inc. Application thérapeutique d'anticorps chimériques et radio-marqués contre l'antigène à différentiation restreinte des lymphocytes B humains pour le traitement du lymphome des cellules B
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
IL110852A (en) 1993-09-02 1999-05-09 Dartmouth College Methods of prolonged suppression of humoral activity
WO1995006481A1 (fr) 1993-09-02 1995-03-09 Trustees Of Dartmouth College Procedes permettant d'induire la tolerance des cellules t a specificite antigenique
EP0731842A1 (fr) 1993-12-03 1996-09-18 Medical Research Council Proteines et peptides de liaison recombines
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
AU693713B2 (en) 1995-06-07 1998-07-02 Immunex Corporation CD40L mutein
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
NL1003537C2 (nl) 1996-07-08 1998-01-12 Holland Railconsult B V Werkwijze voor het vervaardigen van een gebogen beglazing.
WO1998052606A1 (fr) 1997-05-17 1998-11-26 Biogen, Inc. Utilisation d'un interrupteur de fixation cd40:cd154 pour prevenir les reponses immunitaires indesirables, en particulier le rejet de greffe
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
KR20010072564A (ko) 1998-04-03 2001-07-31 존 에프. 카바나프 루푸스 및 관련된 신장 질환의 치료 및/또는 반전에사용되는 안티 ｇｐ39 항체의 용도
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
GB9915653D0 (en) 1999-07-06 1999-09-01 Bruce Terry Hose clamp
EP1221973B1 (fr) * 1999-10-04 2007-05-30 Novartis Vaccines and Diagnostics, Inc. Antagonistes de CD40 permettant de traiter le psoriasis
EP1242438B1 (fr) 1999-12-29 2006-11-08 Immunogen, Inc. Agents cytotoxiques comprenant des doxorubicines et des daunorubicines modifiees et utilisation therapeutique de ceux-ci
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
GB0006398D0 (en) 2000-03-16 2000-05-03 Novartis Ag Organic compounds
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
KR20120090094A (ko) 2003-06-13 2012-08-16 바이오겐 아이덱 엠에이 인코포레이티드 아글리코실 항-ｃｄ154(ｃｄ40 리간드) 항체 및 이의 용도
CN107213469A (zh) 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
EP2399936A3 (fr) * 2004-07-26 2012-02-22 Biogen Idec MA Inc. Anticorps anti-CD154
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006081139A2 (fr) 2005-01-26 2006-08-03 Abgenix, Inc. Anticorps diriges contre interleukine-1 beta
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
WO2006125201A2 (fr) 2005-05-19 2006-11-23 Centocor, Inc. Anticorps anti-muteines mcp-1 biotine-pegylees, compositions, procedes et utilisations correspondants
US8114964B2 (en) 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
EP2035456A1 (fr) 2006-06-22 2009-03-18 Novo Nordisk A/S Production d'anticorps bispécifiques
CL2007002567A1 (es) * 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
EP2097170A4 (fr) 2006-11-20 2010-04-07 Nanostellar Inc Procédé de production de catalyseurs hétérogènes contenant des nanoparticules métalliques
EP2125894B1 (fr) 2007-03-22 2018-12-19 Biogen MA Inc. Protéines de liaison, incluant des anticorps, dérivés d'anticorps et fragments d'anticorps, qui se lient spécifiquement à cd154 et leurs utilisations
EP2139924B1 (fr) 2007-03-29 2016-07-06 Genmab A/S Anticorps bispécifiques et procédés de production de ceux-ci
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
ES2564523T3 (es) 2007-12-19 2016-03-23 Janssen Biotech, Inc. Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
WO2010045340A1 (fr) 2008-10-14 2010-04-22 Centocor Ortho Biotech Inc. Procédés d’humanisation et de maturation d’affinité d’anticorps
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
PL2506871T3 (pl) 2009-11-30 2017-03-31 Janssen Biotech, Inc Przeciwciała ze zmutowanymi regionami Fc i utraconymi funkcjami efektorowymi
US20110206672A1 (en) 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
PL2560993T3 (pl) 2010-04-20 2024-11-04 Genmab A/S Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
CA2797981C (fr) 2010-05-14 2019-04-23 Rinat Neuroscience Corporation Proteines heterodimeriques et leurs procedes de production et de purification
US8795950B2 (en) 2010-06-30 2014-08-05 Jonghan Choi Method of improving print performance in flexographic printing plates
EP2420253A1 (fr) 2010-08-20 2012-02-22 Leadartis, S.L. Synthèse de molécules polyvalentes et multifonctionnelles avec un domaine de trimérisation de collagène XV
EP2444101A1 (fr) 2010-10-21 2012-04-25 Universitätsklinikum Freiburg Ciblage sélectif de l'interaction CD40L/Mac-1 par des inhibiteurs de petits peptides et son utilisation pour la traitement de l'inflammation et de l'athérogénèse
WO2012058137A2 (fr) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Procédés de diversification d'anticorps, anticorps en dérivant et leurs utilisations
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
EP2654780B1 (fr) 2010-12-23 2017-02-01 Janssen Biotech, Inc. Mutants fc actifs d'anticorps résistants à une protéase
US9133272B2 (en) * 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents
CA2832281C (fr) * 2011-04-04 2019-11-05 Trustees Of Dartmouth College Anticorps anti-cd154 ayant une liaison deterioree au fcr et/ou des proprietes de liaison au complement deterioree et leur utilisation dans des therapies immunologiques
DK2771022T3 (da) 2011-10-11 2020-09-28 Viela Bio Inc Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
CN104736168B (zh) 2012-05-31 2018-09-21 索伦托治疗有限公司 与pd-l1结合的抗原结合蛋白
EP4269602A3 (fr) 2012-12-14 2023-12-27 OmniAB, Inc. Polynucléotides codant pour des anticorps de rongeur ayant des idiotypes humains, et animaux les comprenant
KR20180030917A (ko) * 2015-08-05 2018-03-26 얀센 바이오테크 인코포레이티드 항-cd154 항체 및 그의 사용 방법
US10651781B2 (en) 2017-08-24 2020-05-12 Corning Incorporated Glass roof shingle

Also Published As

Publication number Publication date
ECSP18008922A (es) 2018-04-30
JP2018522562A (ja) 2018-08-16
JP7049988B2 (ja) 2022-04-07
CN114605549A (zh) 2022-06-10
PH12018500203A1 (en) 2018-07-30
IL293065A (en) 2022-07-01
NZ739597A (en) 2021-03-26
IL256997A (en) 2018-03-29
MX2018001522A (es) 2018-03-15
CN107921128B (zh) 2022-04-26
NI201800017A (es) 2018-08-24
HK1256804A1 (zh) 2019-10-04
KR20180030917A (ko) 2018-03-26
ES2944982T3 (es) 2023-06-27
CL2018000298A1 (es) 2018-05-11
SG10201913275QA (en) 2020-02-27
JP2022058414A (ja) 2022-04-12
PE20180802A1 (es) 2018-05-09
EP3331563A1 (fr) 2018-06-13
EA201890434A1 (ru) 2018-10-31
CN107921128A (zh) 2018-04-17
MY188405A (en) 2021-12-08
AU2016301361B2 (en) 2022-06-16
US10669343B2 (en) 2020-06-02
CO2018001256A2 (es) 2018-05-10
BR112018002319A2 (pt) 2018-12-11
US11421037B2 (en) 2022-08-23
EP3331563A4 (fr) 2019-09-04
CA2994825A1 (fr) 2017-02-09
AU2016301361A1 (en) 2018-02-08
IL256997B (en) 2022-06-01
US20200317794A1 (en) 2020-10-08
EP3331563B1 (fr) 2023-04-19
US20170037136A1 (en) 2017-02-09
SV2018005624A (es) 2018-09-25
UA123398C2 (uk) 2021-03-31
WO2017024146A1 (fr) 2017-02-09
GT201800034A (es) 2019-09-26
PH12018500203B1 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
FR23C1004I2 (fr) Antagonistes du fcrn et procédés d'utilisation
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA51552A (fr) Anticorps anti-ox40 et procédés d'utilisation
MA45573A (fr) Anticorps anti-cd154 et procédés d'utilisation correspondant
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
EP3394065A4 (fr) Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
EP3303435A4 (fr) Hydrofluoroléfines et procédés d'utilisation associés
EP3383914A4 (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA44524A (fr) Néoantigènes et leurs procédés d'utilisation
MA42979A (fr) Anticorps anti-age et procédés d'utilisation correspondants
MA40921A (fr) Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
EP2986623A4 (fr) 19-nor-c21-n-pyrazolyl-stéroïdes c3,3-disubstitués et procédés d'utilisation de ceux-ci
EP3298168A4 (fr) Agents réducteurs stabilisés et leurs procédés d'utilisation
EP3394098A4 (fr) Anticorps anti-myostatine et procédés d'utilisation
MA55097A (fr) Oxystérols et leurs procédés d'utilisation
MA55063A (fr) Anticorps humanisés cd19 antihumains et procédés d'utilisation
EP2970156A4 (fr) Benzoxazoles substitués et leurs procédés d'utilisation
EP2971000A4 (fr) Polypeptides phi-4 et leurs procédés d'utilisation
EP3436476A4 (fr) Anticorps anti-ryk et leurs procédés d'utilisation
EP3635000A4 (fr) Manabodies et procédés d'utilisation
MA43385A (fr) Nouveaux anticorps anti-claudine et méthodes d'utilisation